普洛藥業(000739.SZ)與碩騰比利時簽署主供貨協議進一步做優做強CDMO業務
格隆匯8月22日丨普洛藥業(000739.SZ)公佈,公司與碩騰公司合作多年,已經建立了良好的合作關係。雙方為進一步深化合作,公司與其下屬公司Zoetis Belgium S.A.(“碩騰比利時”)於近日簽署了《主供貨協議》,就原合作項目的產品供應和新增三個CDMO項目的技術轉移、生產等條款達成約定。
碩騰公司是全球最大的動物用藥和疫苗廠商。主營業務為針對家畜和寵物用藥的研究、開發、生產和銷售。碩騰公司為公司的重要客户之一,2017年和2018年公司對碩騰公司的銷售額分別為945萬美元和1107萬美元,佔公司出口業務比重約為2.6%和2.4%。
此次合作是公司根據發展戰略,為充分發揮雙方各自優勢,實現長期合作,進一步做優做強公司CDMO業務,提升公司的綜合競爭能力而開展的。該協議的簽署有助於雙方合作的進一步深化和發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.